Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer.

Gary N Schwartz Peter A Kaufman Karthik V Giridhar Jonathan D Marotti Mary D Chamberlin Bradley A Arrick Grace Makari-Judson Matthew P Goetz Shannon M Soucy Fred Kolling Iv Eugene Demidenko Todd W Miller

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Alternating 17b-estradiol/aromatase inhibitor therapy may be a promising treatment for endocrine-refractory ER+ breast cancer, including following progression on CDK4/6 inhibitors or everolimus. Further study is warranted to determine whether the anti-tumor activity of 17b-estradiol differs according to ESR1 mutation status.

Keyphrases

estrogen receptor
breast cancer cells
young adults
bone marrow
combination therapy